Combination therapy of lanifibranor and firsocostat further improves steatohepatitis and fibrosis compared to monotherapy in a diet-induced murine model of NASH

Authors, G. WETTSTEIN 1, F. BRIAND 2, T. SULPICE 2, J.-L. JUNIEN 1, P. BROQUA 1
1 Inventiva, Dax, France
2 Physiogenex, Escalquens, France

INTRODUCTION
Lanifibranor, a panPPAR agonist showed clinical efficacy on both resolution of NASH and fibrosis improvement in patients with NASH (NATIVE study). Firsocostat, an ACC1/2 inhibitor, reduced liver fat and markers of fibrosis in patients with advanced fibrosis due to NASH. ACC inhibitors inhibit de novo lipogenesis and reactivates beta oxidation, whilst PPARs stimulate lipid catabolism and redirect hepatic lipids to adipocytes. The potential complementary mode of action of both compounds provides a rationale to investigate whether their combination has additive effects in a nonclinical model of NASH and fibrosis.

METHOD
Mice were fed a 60% high fat/1.25% cholesterol/0.5% cholic acid diet with 2% 2-hydroxypropyl beta-cyclodextrin in drinking water for 3 weeks. After 1 week of diet, mice were randomized according to their ALT, AST plasma levels and body weight and were orally treated (QD) for 2 weeks either with vehicle, lanifibranor (suboptimal dose: 10 mg/kg), firsocostat (15 mg/kg) or the combination lanifibranor and firsocostat. Biochemistry, liver histology and gene expression were analyzed.

RESULTS
Pilot study in this model was conducted to evaluate dose-response of lanifibranor. We chose for the combination study the dose of 10 mg/kg as a suboptimal dose for lanifibranor. 30 mg/kg being the optimal dose in this model with substantial and significant reduction of steatosis, inflammation and fibrosis.

Effect of lanifibranor, firsocostat and combination on body weight

Lanifibranor had no effect on body weight. Firsocostat was initially given at 30 mg/kg but induced body weight lost alone and a drastic body weight decrease in combination with lanifibranor. At day 6 the dose was change to 15 mg/kg in the firsocostat group as well as in the combination group.

Combination therapy further decreases hepatic lipids content

In this condition neither lanifibranor nor firsocostat alone had an effect on hepatic lipids content (except for lanifibranor on total cholesterol). However the combination of the two drugs lead to a significant reduction of hepatic lipids content.

CONCLUSIONS
Lanifibranor and firsocostat combination reached greater efficacy than monotherapy at the selected doses on hepatic lipid content, steatosis, fibrosis and total scoring. These data emphasize the complementary effect of these two compounds on lipids metabolic leading to further improvement of NASH and fibrosis. These data would support clinical investigation of a combination of lanifibranor and firsocostat in patients with NASH.

CONTACT INFORMATION
Guillaume.wettstein@inventivapharma.com